Sensus Healthcare Inc
NASDAQ:SRTS
Intrinsic Value
Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. [ Read More ]
The intrinsic value of one SRTS stock under the Base Case scenario is 6.1 USD. Compared to the current market price of 3.28 USD, Sensus Healthcare Inc is Undervalued by 46%.
Valuation Backtest
Sensus Healthcare Inc
Run backtest to discover the historical profit from buying and selling SRTS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Sensus Healthcare Inc
Current Assets | 49.5m |
Cash & Short-Term Investments | 23.1m |
Receivables | 10.6m |
Other Current Assets | 15.7m |
Non-Current Assets | 4.2m |
PP&E | 1.2m |
Other Non-Current Assets | 2.9m |
Current Liabilities | 4.2m |
Accounts Payable | 2.8m |
Accrued Liabilities | 187k |
Other Current Liabilities | 1.2m |
Non-Current Liabilities | 656k |
Other Non-Current Liabilities | 656k |
Earnings Waterfall
Sensus Healthcare Inc
Revenue
|
24.4m
USD
|
Cost of Revenue
|
-10.3m
USD
|
Gross Profit
|
14.1m
USD
|
Operating Expenses
|
-14.4m
USD
|
Operating Income
|
-382k
USD
|
Other Expenses
|
867k
USD
|
Net Income
|
485k
USD
|
Free Cash Flow Analysis
Sensus Healthcare Inc
SRTS Profitability Score
Profitability Due Diligence
Sensus Healthcare Inc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Sensus Healthcare Inc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
SRTS Solvency Score
Solvency Due Diligence
Sensus Healthcare Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Sensus Healthcare Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SRTS Price Targets Summary
Sensus Healthcare Inc
According to Wall Street analysts, the average 1-year price target for SRTS is 6.8 USD with a low forecast of 5.05 USD and a high forecast of 8.4 USD.
Ownership
SRTS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SRTS Price
Sensus Healthcare Inc
Average Annual Return | 11.8% |
Standard Deviation of Annual Returns | 54.4% |
Max Drawdown | -88% |
Market Capitalization | 53.7m USD |
Shares Outstanding | 16 271 097 |
Percentage of Shares Shorted | 0.23% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida and currently employs 37 full-time employees. The company went IPO on 2016-06-03. The firm is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The firm uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The firm incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100 Plus and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100 Plus offers remote diagnostics solutions, including operation tracking.
Contact
IPO
Employees
Officers
The intrinsic value of one SRTS stock under the Base Case scenario is 6.1 USD.
Compared to the current market price of 3.28 USD, Sensus Healthcare Inc is Undervalued by 46%.